Cargando…
Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran
BACKGROUND: Hepatitis A virus (HAV) is a major cause of acute viral hepatitis worldwide. Annual medical and work loss costs of hepatitis A are significant even in low-endemic countries. It is recommended that each country should collect and review the information needed to estimate its national burd...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078371/ https://www.ncbi.nlm.nih.gov/pubmed/25002897 |
_version_ | 1782323726654636032 |
---|---|
author | Farajzadegan, Ziba Hoseini, Shervin Ghaffari Kelishadi, Roya Jamshidi, Fahimeh Nokhodian, Zari Noori, Rasool Mirmoghtadaee, Parisa Hovsepian, Silva Mostafavi, Seyyed-Nassereddin |
author_facet | Farajzadegan, Ziba Hoseini, Shervin Ghaffari Kelishadi, Roya Jamshidi, Fahimeh Nokhodian, Zari Noori, Rasool Mirmoghtadaee, Parisa Hovsepian, Silva Mostafavi, Seyyed-Nassereddin |
author_sort | Farajzadegan, Ziba |
collection | PubMed |
description | BACKGROUND: Hepatitis A virus (HAV) is a major cause of acute viral hepatitis worldwide. Annual medical and work loss costs of hepatitis A are significant even in low-endemic countries. It is recommended that each country should collect and review the information needed to estimate its national burden of hepatitis A to provide evidence for health policy makers to implement appropriate and cost-effective preventive strategy for HAV infection. The objective of this study was to estimate accurate prevalence of HAV infection in Iran for best preventive measures. MATERIALS AND METHODS: MEDLINE, Institute of Scientific Information, Scopus, Iranmedex, Irandoc, Magiran and Scientific Information Database were searched. The seroprevalence of HAV were pooled by age, sex and residence using fixed and random effect models. RESULTS: Sixteen papers representing 11857 subjects were included. The overall HAV seroprevalence was 51% (confidence interval [CI] 95%: 50-52%) in fixed and 66% (95% CI: 50-79%) in random effects models. The prevalence was 32% (CI 95%: 11-63%) in less than 20, 50% (CI 95%: 24-75%) in 20-30, and 67% (CI 95%: 17-95%) in more than 30 years of age. The difference was not significant in gender or residence subgroups. CONCLUSION: HAV infection in Iran may be considered as low or very low. Therefore, targeted vaccination of high-risk groups and more improvement in environmental sanitation would be the best preventive measure. |
format | Online Article Text |
id | pubmed-4078371 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-40783712014-07-07 Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran Farajzadegan, Ziba Hoseini, Shervin Ghaffari Kelishadi, Roya Jamshidi, Fahimeh Nokhodian, Zari Noori, Rasool Mirmoghtadaee, Parisa Hovsepian, Silva Mostafavi, Seyyed-Nassereddin J Res Med Sci Review Article BACKGROUND: Hepatitis A virus (HAV) is a major cause of acute viral hepatitis worldwide. Annual medical and work loss costs of hepatitis A are significant even in low-endemic countries. It is recommended that each country should collect and review the information needed to estimate its national burden of hepatitis A to provide evidence for health policy makers to implement appropriate and cost-effective preventive strategy for HAV infection. The objective of this study was to estimate accurate prevalence of HAV infection in Iran for best preventive measures. MATERIALS AND METHODS: MEDLINE, Institute of Scientific Information, Scopus, Iranmedex, Irandoc, Magiran and Scientific Information Database were searched. The seroprevalence of HAV were pooled by age, sex and residence using fixed and random effect models. RESULTS: Sixteen papers representing 11857 subjects were included. The overall HAV seroprevalence was 51% (confidence interval [CI] 95%: 50-52%) in fixed and 66% (95% CI: 50-79%) in random effects models. The prevalence was 32% (CI 95%: 11-63%) in less than 20, 50% (CI 95%: 24-75%) in 20-30, and 67% (CI 95%: 17-95%) in more than 30 years of age. The difference was not significant in gender or residence subgroups. CONCLUSION: HAV infection in Iran may be considered as low or very low. Therefore, targeted vaccination of high-risk groups and more improvement in environmental sanitation would be the best preventive measure. Medknow Publications & Media Pvt Ltd 2014-03 /pmc/articles/PMC4078371/ /pubmed/25002897 Text en Copyright: © Journal of Research in Medical Sciences http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Farajzadegan, Ziba Hoseini, Shervin Ghaffari Kelishadi, Roya Jamshidi, Fahimeh Nokhodian, Zari Noori, Rasool Mirmoghtadaee, Parisa Hovsepian, Silva Mostafavi, Seyyed-Nassereddin Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran |
title | Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran |
title_full | Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran |
title_fullStr | Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran |
title_full_unstemmed | Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran |
title_short | Systematic review and meta-analysis on the age-specific seroprevalence of hepatitis A in Iran |
title_sort | systematic review and meta-analysis on the age-specific seroprevalence of hepatitis a in iran |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078371/ https://www.ncbi.nlm.nih.gov/pubmed/25002897 |
work_keys_str_mv | AT farajzadeganziba systematicreviewandmetaanalysisontheagespecificseroprevalenceofhepatitisainiran AT hoseinishervinghaffari systematicreviewandmetaanalysisontheagespecificseroprevalenceofhepatitisainiran AT kelishadiroya systematicreviewandmetaanalysisontheagespecificseroprevalenceofhepatitisainiran AT jamshidifahimeh systematicreviewandmetaanalysisontheagespecificseroprevalenceofhepatitisainiran AT nokhodianzari systematicreviewandmetaanalysisontheagespecificseroprevalenceofhepatitisainiran AT noorirasool systematicreviewandmetaanalysisontheagespecificseroprevalenceofhepatitisainiran AT mirmoghtadaeeparisa systematicreviewandmetaanalysisontheagespecificseroprevalenceofhepatitisainiran AT hovsepiansilva systematicreviewandmetaanalysisontheagespecificseroprevalenceofhepatitisainiran AT mostafaviseyyednassereddin systematicreviewandmetaanalysisontheagespecificseroprevalenceofhepatitisainiran |